Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Shares Outstanding (Diluted Average) (2021 - 2026)

Axsome Therapeutics' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $51.2 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 4.76% to $51.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $51.2 million, a 4.76% increase, with the full-year FY2025 number at $49.7 million, up 3.83% from a year prior.
  • Shares Outstanding (Diluted Average) hit $51.2 million in Q1 2026 for Axsome Therapeutics, up from $49.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for AXSM hit a ceiling of $51.2 million in Q1 2026 and a floor of $38.3 million in Q1 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $45.8 million across 5 years, with a median of $47.4 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 13.57% in 2023 and later grew 1.24% in 2024.
  • Tracing AXSM's Shares Outstanding (Diluted Average) over 5 years: stood at $40.7 million in 2022, then grew by 11.73% to $45.4 million in 2023, then rose by 5.48% to $47.9 million in 2024, then increased by 3.83% to $49.7 million in 2025, then rose by 2.92% to $51.2 million in 2026.
  • Business Quant data shows Shares Outstanding (Diluted Average) for AXSM at $51.2 million in Q1 2026, $49.7 million in Q4 2025, and $50.0 million in Q3 2025.